Vfend Adds Candidiasis Indication; Label Notes QTc Effect Under 10 Msec
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Revised Vfend labeling adding an esophageal candidiasis indication includes results of an FDA-requested study showing that the antifungal increases QTc by less than 10 milliseconds.
You may also be interested in...
Pfizer Vfend Cardiac Safety Studies Needed For Esophageal Candida Approval
Approval of Pfizer’s Vfend for treatment of esophageal candidiasis depends on completion of cardiac studies to rule out an unacceptable risk of QTc prolongation, review documents for the triazole antifungal indicate.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product